Clinical trials: Neoadjuvant Treatment
Breast Cancer, HER2-negative Breast Cancer
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
NSABP FB-9 is a Phase II, multi-center, randomized study of eribulin or weekly paclitaxel followed by doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for women with HER2-negative, operable and locally advanced breast…
- Trial name
- NCT01705691
- Testing
- Paclitaxel, Eribulin, Doxorubicin
- Where
- 20 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- NSABP Foundation Inc
Pancreatic Cancer
Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
A standard treatment for pancreatic cancer is radiation therapy plus chemotherapy after surgery. Radiation therapy and chemotherapy are commonly given for up to six weeks.
- Trial name
- NCT00438256
- Testing
- Proton Beam Radiation, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Non-small Cell Lung Carcinoma
Neoadjuvant Pembrolizumab
This multi-institutional, phase 2 clinical trial is studying two doses of pembrolizumab administered prior to surgery (neoadjuvant therapy) and 4 doses administered after surgery (adjuvant therapy) for stage IB, II or IIIA…
- Trial name
- TOP 1501 (NCT02818920)
- Testing
- Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Neal Ready MD PhD
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
This phase II trial studies how well nab-paclitaxel and alpelisib works in treating patients with triple negative breast cancer with PIK3CA or PTEN alterations that does not respond to anthracycline chemotherapy (anthrocycline…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04216472
- Testing
- Alpelisib, Nab-paclitaxel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
ER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
To demonstrate whether addition of MM-121 to paclitaxel is more effective than treatment with paclitaxel alone, when administered as part of the neoadjuvant treatment in Her2 negative locally advanced operable breast cancer…
- Trial name
- NCT01421472
- Testing
- MM-121, Paclitaxel
- Where
- 38 sites in United States
- Volunteers
- 196 people
- Sponsor
- Merrimack Pharmaceuticals
Leukemia, Lymphoma
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002766
- Testing
- dactinomycin, sargramostim, carmustine
- Where
- 7 sites in United States
- Volunteers
- 170 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer
CHFR Methylation Status Esophageal Cancer Study
This is a Phase 2 Study of Paclitaxel with Cisplatin versus Fluoropyrimidine with a Platinum Agent for Neoadjuvant Therapy in Operable Esophageal Cancer Based on CHFR Methylation Status in Diagnostic Biopsies.
- Trial name
- J10130 (NCT01372202)
- Testing
- Paclitaxel, Cisplatin, Oxaliplatin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ulcerative Colitis
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis…
- Trial name
- OCTAVE (NCT01458951)
- Testing
- tofacitinib
- Where
- 182 sites in United States, Australia and 27 more
- Volunteers
- 547 people
- Sponsor
- Pfizer
Colon Cancer
Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer
The purpose of this study is to see if giving chemo-therapy for colon cancer before surgery can shrink the cancer and lead to a higher rate of cure than operating first and then giving chemotherapy.
- Trial name
- NCT00826800
- Testing
- FOLFOX and bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.
- Trial name
- NCT04436029
- Testing
- Descartes 11
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Cartesian Therapeutics
Kidney Failure, Chronic, Kidney Transplantation
Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
The purpose of this study is to evaluate the safety of alemtuzumab after kidney transplantation as part of a multitherapy regimen to prevent kidney graft loss and death and to avoid steroids and chronic use of calcineurin…
- Conditions
- Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
- Trial name
- NCT00240994
- Testing
- Alemtuzumab, Tacrolimus, Mycophenolate mofetil
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00757172
- Testing
- panitumumab, cisplatin, docetaxel
- Where
- 21 sites in United States
- Volunteers
- 70 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Ductal Adenocarcinoma
Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma
The purpose of this study is to determine if study treatment with atezolizumab and PEGPH20 given before and after surgery, followed by chemotherapy is safe and if it can further increase the immune response against the tumor…
- Trial name
- NEOiPANC (NCT03979066)
- Testing
- Atezolizumab, PEGPH20
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Gulam Manji
Melanoma, Malignant Melanoma
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
- Conditions
- Melanoma, Malignant Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma
- Trial name
- NCT01321437
- Testing
- therapeutic conventional surgery, laboratory biomarker analysis, Axitinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, Irvine
Cognitive Decline, Chemo-brain
Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer
Purpose: To conduct a one-arm phase II trial to: (1) compare changes in pre- to post-chemotherapy cognitive function in a cohort of patients with breast cancer receiving memantine to historical controls; (2) examine how…
- Trial name
- NCT04033419
- Testing
- Memantine
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Colorectal Cancer
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
FC-6 is a Phase II, multi-center clinical trial for patients with unresectable, wild-type K-RAS, colorectal cancer with metastases confined to the liver.
- Trial name
- NCT00803647
- Testing
- cetuximab, 5-FU, oxaliplatin
- Where
- 23 sites in United States
- Volunteers
- 20 people
- Sponsor
- NSABP Foundation Inc
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
This pilot, phase II trial studies the side effects of giving bortezomib together with combination chemotherapy and to see how well it works in treating young patients with relapsed acute lymphoblastic leukemia or lymphoblastic…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma
- Trial name
- NCT00873093
- Testing
- L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone
- Where
- 171 sites in United States, Australia and 2 more
- Volunteers
- 148 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Head and Neck
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
There are currently no useful tests to identify patients who will respond to cetuximab therapy, notably because EGFR levels do not correlate with the clinical responses observed.
- Trial name
- NCT01218048
- Testing
- Cetuximab, Surgery, Post-surgical radiation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Robert Ferris
Breast Cancer
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
This research is being done to determine if early changes on a type of imaging procedure called PET (Positron Emission Tomography) can predict which patients are most likely to respond to the combination of trastuzumab and…
- Trial name
- NCT01937117
- Testing
- Positron emission tomography (PET), Trastuzumab, Pertuzumab
- Where
- 10 sites in United States
- Volunteers
- 88 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma.
- Conditions
- Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
- Trial name
- NCT03698019
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 815 sites in United States
- Volunteers
- 313 people
- Sponsor
- National Cancer Institute (NCI)